


Formula #: 1807
Rev #:1
Date: May 8, 2024



102-2440 Canoe Ave
Coquitlam BC V3K 6C2
Canada

Gabapentin 10%, Diphenhydramine HCl 5%, Lidocaine HCl 2% in Transderma MultiMax Cream

Ingredients	Makes 100 g
Gabapentin	10 g
Diphenhydramine Hydrochloride	5 g
Lidocaine Hydrochloride	2 g
Ethoxy diglycol	5 mL
Transderma MultiMax Cream	qs 100 g

Notes:

*Propylene glycol may be substituted for the ethoxy diglycol.

If the final consistency of the cream is less than ideal, add Xenefix Derm600 in a dropwise fashion, mixing well between additions, until the desired consistency is achieved.

Application:

The combination of topical analgesics can be used for the treatment of neuropathic pain.¹⁻³


Compounding Procedure:⁴⁻⁷

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weight and/or measure each ingredient
3. In a glass mortar mix the powders together and reduce to a fine particle size. Passing the powder blend through a fine mesh sieve will ensure a uniform particle size.
4. Add the ethoxy diglycol to the powder to form a smooth paste
5. Incorporate Transderma's® MultiMax Cream Base geometrically with the paste to final weight; mix well
6. Shear force mixing (electronic mortar & pestle) and/or milling may be necessary to homogenously distribute the APIs throughout the base and facilitate the creation of a pharmaceutically elegant final preparation
7. Package and label

Packaging and Labelling:

Disclaimer: Xenex Laboratories Inc. has provided the formula and instructions above as a model for educational purposes only on the basis of recognized compendia and texts or references. Xenex Laboratories Inc. takes no responsibility for the validity or accuracy of this information or for its safety or effectiveness, nor for any use thereof, which is at the sole risk of the licensed pharmacist. Adjustments may be needed to meet specific patient needs and in accordance with a licensed prescriber's prescription. The pharmacist must employ appropriate tests to determine the stability of this suggested formula. Xenex Laboratories Inc., its owners, officers, agents, contractors, affiliates and employees cannot be held liable to any person or entity concerning claims, loss or damage caused by, or alleged to be caused by, directly or indirectly, the use or misuse of the information contained in this suggested formula. In all cases, it is the responsibility of the licensed pharmacist to know the law, to compound any finished product and to dispense these products in accordance with Health Canada and FDA guidelines and appropriate Provincial Drug Schedules and Provincial or Territorial Pharmacy Practice Standards.

Formula #: 1807
Rev #:1
Date: May 8, 2024



102-2440 Canoe Ave
Coquitlam BC V3K 6C2
Canada

For external use only, keep away from eyes and mucous membranes, apply exact dose topically as directed.
Store at controlled room temperatures.

Beyond Use Date:

30 days⁸

References:

1. Gabapentin. *UpToDate*. Waltham, MA.: UpToDate; 2024. www.uptodate.com. Accessed April 14, 2024
2. Diphenhydramine. *UpToDate*. Waltham, MA.: UpToDate; 2024. www.uptodate.com. Accessed April 14, 2024
3. Lidocaine. *UpToDate*. Waltham, MA.: UpToDate; 2024. www.uptodate.com. Accessed April 14, 2024
4. Loyd A. Amitriptyline Hydrochloride 2%, Carbamazepine 2%, Gabapentin 10%, and Ketoprofen 2% Transdermal Gel. *Int J Pharm Compd*. 2011;15:157
5. Amitriptyline Hydrochloride 10%, Baclofen 2.5% and Ketamine Hydrochloride 5% in Lipopen™ Ultra Base [Fagron Freedom]. *CompoundingToday*. Edmond, OK. International Journal of Pharmaceutical Compounding; 2024. www.compoundingtoday.com. Accessed April 14, 2024
6. Bupivacaine Hydrochloride 1%, Diclofenac Sodium 3%, Gabapentin 3%, Ketamine Hydrochloride 10%, Orphenadrine Citrate 5% and Pentoxifylline 3% in Versatile™ Cream [Fagron]. *CompoundingToday*. Edmond, OK. International Journal of Pharmaceutical Compounding; 2024. www.compoundingtoday.com. Accessed April 14, 2024
7. Cyclobenzaprine Hydrochloride 20-mg/g, Ketoprofen 200-mg/g and Lidocaine 100-mg/g in Lipoderm™ [PCCA]. *CompoundingToday*. Edmond, OK. International Journal of Pharmaceutical Compounding; 2024. www.compoundingtoday.com. Accessed April 14, 2024
8. National Association of Pharmacy Regulatory Authorities, Guidance Document for Pharmacy Compounding of Non-Sterile Preparations. June 2018

Disclaimer: Xenex Laboratories Inc. has provided the formula and instructions above as a model for educational purposes only on the basis of recognized compendia and texts or references. Xenex Laboratories Inc. takes no responsibility for the validity or accuracy of this information or for its safety or effectiveness, nor for any use thereof, which is at the sole risk of the licensed pharmacist. Adjustments may be needed to meet specific patient needs and in accordance with a licensed prescriber's prescription. The pharmacist must employ appropriate tests to determine the stability of this suggested formula. Xenex Laboratories Inc., its owners, officers, agents, contractors, affiliates and employees cannot be held liable to any person or entity concerning claims, loss or damage caused by, or alleged to be caused by, directly or indirectly, the use or misuse of the information contained in this suggested formula. In all cases, it is the responsibility of the licensed pharmacist to know the law, to compound any finished product and to dispense these products in accordance with Health Canada and FDA guidelines and appropriate Provincial Drug Schedules and Provincial or Territorial Pharmacy Practice Standards.